Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call
Sangamo Therapeutics (Nasdaq: SGMO), a genomic medicine company, has scheduled its second quarter 2025 financial results release for Thursday, August 7, 2025, after market close. The company will host a conference call at 4:30 p.m. Eastern the same day to discuss financial results and provide business updates.
Participants can register and access the call through a provided link, with a recommended join time of 10 minutes before the event. The webcast will be available in the Investors and Media section of Sangamo's website, with a replay accessible after the call.
[]Sangamo Therapeutics (Nasdaq: SGMO), un'azienda di medicina genomica, ha programmato la pubblicazione dei risultati finanziari del secondo trimestre 2025 per giovedì 7 agosto 2025, dopo la chiusura del mercato. La società terrà una conference call alle 16:30 ora Eastern dello stesso giorno per discutere i risultati finanziari e fornire aggiornamenti aziendali.
I partecipanti possono registrarsi e accedere alla chiamata tramite un link fornito, con un orario di ingresso consigliato di 10 minuti prima dell'evento. Il webcast sarà disponibile nella sezione Investitori e Media del sito web di Sangamo, con una replica accessibile dopo la chiamata.
Sangamo Therapeutics (Nasdaq: SGMO), una compañía de medicina genómica, ha programado la publicación de sus resultados financieros del segundo trimestre de 2025 para el jueves 7 de agosto de 2025, después del cierre del mercado. La empresa realizará una conferencia telefónica a las 4:30 p.m. hora Eastern el mismo día para discutir los resultados financieros y ofrecer actualizaciones comerciales.
Los participantes pueden registrarse y acceder a la llamada a través de un enlace proporcionado, recomendándose unirse 10 minutos antes del evento. La transmisión estará disponible en la sección de Inversores y Medios del sitio web de Sangamo, con una repetición accesible después de la llamada.
Sangamo Therapeutics (나스닥: SGMO)는 유전체 의학 회사로서 2025년 2분기 재무 결과를 2025년 8월 7일 목요일 장 마감 후에 발표할 예정입니다. 회사는 같은 날 동부 시간 오후 4시 30분에 컨퍼런스 콜을 개최하여 재무 결과를 논의하고 사업 현황을 업데이트할 예정입니다.
참가자는 제공된 링크를 통해 등록하고 콜에 접속할 수 있으며, 행사 시작 10분 전 접속을 권장합니다. 웹캐스트는 Sangamo 웹사이트의 투자자 및 미디어 섹션에서 제공되며, 콜 종료 후 재청취도 가능합니다.
Sangamo Therapeutics (Nasdaq : SGMO), une entreprise de médecine génomique, a programmé la publication de ses résultats financiers du deuxième trimestre 2025 pour le jeudi 7 août 2025, après la clôture des marchés. La société organisera une conférence téléphonique à 16h30 heure de l'Est le même jour pour discuter des résultats financiers et fournir des mises à jour commerciales.
Les participants peuvent s'inscrire et accéder à l'appel via un lien fourni, avec un délai recommandé de connexion 10 minutes avant l'événement. Le webdiffusion sera disponible dans la section Investisseurs et Médias du site web de Sangamo, avec un replay accessible après l'appel.
Sangamo Therapeutics (Nasdaq: SGMO), ein Unternehmen für Genommedizin, hat die Veröffentlichung der Finanzergebnisse für das zweite Quartal 2025 für Donnerstag, den 7. August 2025, nach Börsenschluss, geplant. Das Unternehmen wird am selben Tag um 16:30 Uhr Eastern Time eine Telefonkonferenz abhalten, um die Finanzergebnisse zu besprechen und Geschäftsaktualisierungen zu geben.
Teilnehmer können sich über einen bereitgestellten Link registrieren und an dem Anruf teilnehmen, empfohlen wird eine Teilnahme 10 Minuten vor Beginn. Das Webcast wird im Bereich Investoren und Medien auf der Website von Sangamo verfügbar sein, mit einer Wiedergabe nach der Telefonkonferenz.
- None.
- None.
RICHMOND, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company today announced that the company has scheduled the release of its second quarter 2025 financial results after the markets close on Thursday, August 7, 2025.
The company will hold a conference call at 4:30 p.m. Eastern on Thursday, August 7, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates.
Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with the number and unique passcode provided, or to use the dial-out option to connect their phone instantly. The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under Events.
A replay will be available following the conference call, accessible under Events.
About Sangamo Therapeutics
Sangamo Therapeutics is a genomic medicine company dedicated to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases who do not have adequate or any treatment options. Sangamo believes that its zinc finger epigenetic regulators are ideally suited to potentially address devastating neurological disorders and that its capsid discovery platform can expand delivery beyond currently available intrathecal delivery capsids, including in the central nervous system. Sangamo’s pipeline also includes multiple partnered programs and programs with opportunities for partnership and investment. To learn more, visit www.sangamo.com and connect with us on LinkedIn and X.
Investor Relations
Louise Wilkie
ir@sangamo.com
Media Inquiries
Melinda Hutcheon
media@sangamo.com
FAQ
When will Sangamo Therapeutics (SGMO) release Q2 2025 earnings?
How can investors access Sangamo's Q2 2025 earnings call?
Will there be a replay available of Sangamo's Q2 2025 earnings call?
What time should participants join Sangamo's Q2 2025 earnings call?
